

VYLOY[™]

zolbetuximab
Powder for Concentrate for
Solution for Infusion 100mg/vial

In advanced* gastric/GEJ cancer,

Testing for Claudin 18.2

with Immunohistochemical (IHC) staining may reveal candidates for targeted first-line treatment with VYLOY + chemotherapy¹.

*Locally advanced unresectable or metastatic.¹

Claudin 18.2 (CLDN18.2) is a highly prevalent, predictive biomarker for advanced* G/GEJ adenocarcinoma²⁻³

- Based on two global Phase 3 clinical trials, it is estimated that:


38% OF PATIENTS with advanced* G/GEJ cancer are CLDN18.2+, which could make them candidates for VYLOY + chemotherapy²⁻³

The 2024 Pan-Asian adapted European Society for Medical Oncology (ESMO) Clinical Practice Guidelines highlighted CLDN18.2 as a validated predicted biomarker for metastatic or unresectable G/GEJ adenocarcinoma.⁴



CLDN18.2

CLDN18.2 is the dominant isoform in normal gastric tissue and is often retained in malignant transformation.⁵



Scan to learn more
about VYLOY

Testing locations

Testing for CLDN18.2+ tumours is available at various labs throughout Malaysia.¹ The following locations are ready to help identify patients with CLDN18.2+ tumours who may be candidates for treatment with VYLOY + chemotherapy.

Subang Jaya Medical Centre Laboratory



Level 4, Mediplex, Subang Jaya Medical Centre No.1, Jalan SS 12/1A, 47500 Subang Jaya, Selangor Darul Ehsan.



+ (603) 5639 1927 / 1924



<https://subangjayamedicalcentre.com/medical-professionals/sjmc-laboratory>

Premier Integrated Labs



Level 21, TNB Dua Sentral, No. 8, Jalan Tun Sambanthan, Brickfields, 50470 Kuala Lumpur, Malaysia.



+ (603) 3345 7000



<https://www.premierintegratedlabs.com.my/>

¹This information is intended as informational and is not intended as a complete list of available testing options. Astellas is not responsible for any test provider and does not endorse any particular diagnostic test. The accuracy and results of diagnostic tests vary, and Astellas is unable to vouch for the accuracy of the lab's methods and tests and thus shall have no liability arising from such testing. Information provided herein should in no way be considered a guarantee of coverage, reimbursement, or patient assistance. Providers should contact third-party laboratories for information on their patient assistance programs. While diagnostic testing may assist providers in identifying appropriate treatment for patients, the decision and action should be decided by a provider in consultation with the patient. All products are trademarks of their respective holders, all rights reserved.

Indication: VYLOY™, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are Claudin (CLDN) 18.2 positive.

References: **1.** VYLOY Malaysia Approved Package Insert. **2.** Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2- positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. *Lancet* (Epub ahead of print) 04-14-2023. **3.** Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. *Nat Med* 2023;29:2133-41. **4.** Shitara K, Fleitas T, Kawakami H, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer. *ESMO Open*. 2024;9(2):102226. doi:10.1016/j.esmoop.2023.102226. **5.** Sahin U, Koslowski M, Dhaene K, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. *Clin Cancer Res* 2008;14(23):7624-34.



To report suspected adverse event(s), please contact: pv.my@astellas.com

For Healthcare Professionals only.

Astellas Pharma Malaysia Sdn Bhd.

Pavilion Damansara Heights, Unit 9.02 and 9.03, Level 9, Corporate Tower 2, 3, Jalan Damanela, Pusat Bandar Damansara, 50490 Kuala Lumpur.

© 2025 Astellas Pharma Inc. All trademarks are the property of their respective owners. All rights reserved.

MAT-MY-VYL-2025-00007 / November 2025.



Scan for full VYLOY
Malaysia Package Insert